FIELD: pharmacology.
SUBSTANCE: ophthalmic composition contains a formula 
compound, where the values for R1 and R2 groups are given in the claims, and an ophthalmologically acceptable carrier. The invention also relates to a method for dry eye treatment, comprising local administration of a therapeutically effective amount of the ophthalmic composition to the eye of the subject in need.
EFFECT: increased efficiency.
20 cl, 6 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL FORMULATIONS OF NON-POLAR AND POLAR LIPIDS FOR OPHTHALMOLOGICAL APPLICATION | 2007 |
|
RU2495661C2 |
| OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR SURFACE DAMAGE AND DRY EYE SYMPTOMS | 2019 |
|
RU2806212C2 |
| LIPID-BASED OPHTHALMIC EMULSION | 2019 |
|
RU2793333C2 |
| METHOD OF TREATING OCULAR DISORDERS WITH COMPOUNDS FOUND IN HARDERIAN GLAND SECRETIONS | 2014 |
|
RU2683943C1 |
| COMPOSITIONS AND METHODS OF TREATING MEIBOMIAN DYSFUNCTION | 2015 |
|
RU2730464C2 |
| COMPOSITIONS BASED ON PARTIALLY FLUORINATED ALKANES, CONTAINING ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | 2019 |
|
RU2808451C2 |
| METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISEASES | 2016 |
|
RU2691412C2 |
| THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | 2014 |
|
RU2709542C2 |
| METHOD OF TREATING BLEPHAROCONJUNCTIVAL FORM OF DRY EYE SYNDROME | 2012 |
|
RU2510701C1 |
| PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING DRY-EYE SYNDROME | 2008 |
|
RU2445098C2 |
